Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease

Yanling Shen,1,2,* Ling Dai,1,* Haibo Tian,1,3 Runnan Xu,1 Fuying Li,4 Zhuohang Li,1 Jeremy Zhou,5 Liping Wang,5 Jianghui Dong,1,5 Liyuan Sun1,4 1Department of Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shen Y, Dai L, Tian H, Xu R, Li F, Li Z, Zhou J, Wang L, Dong J, Sun L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	parkinson’s disease magnesium-l-threonate cerebrospinal fluid magnesium Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/e486498656c3424b9adc2150c98bee6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e486498656c3424b9adc2150c98bee6b
record_format	dspace
spelling	oai:doaj.org-article:e486498656c3424b9adc2150c98bee6b2021-12-02T09:46:04ZTreatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease1178-2021https://doaj.org/article/e486498656c3424b9adc2150c98bee6b2019-11-01T00:00:00Zhttps://www.dovepress.com/treatment-of-magnesium-l-threonate-elevates-the-magnesium-level-in-the-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yanling Shen,1,2,* Ling Dai,1,* Haibo Tian,1,3 Runnan Xu,1 Fuying Li,4 Zhuohang Li,1 Jeremy Zhou,5 Liping Wang,5 Jianghui Dong,1,5 Liyuan Sun1,4 1Department of Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic of China; 2Department of Pathology, Affiliated Chenggong Hospital, Xiamen University, Xiamen, Fujian 361000, People’s Republic of China; 3Department of Pathology, Fuling Central Hospital of Chongqing City, Chongqing 408099, People’s Republic of China; 4Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan; 5School of Pharmacy and Medical Sciences, and UniSA Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia*These authors contributed equally to this workCorrespondence: Jianghui DongDepartment of Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic of ChinaTel +86-773-3680651Fax +86-773-3680230Email Jianghui.dong@mymail.unisa.edu.auLiyuan SunDepartment of Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic of ChinaTel +86-773-5893516Fax +86-773-5898939Email sunly@glmc.edu.cnPurpose: Epidemiology research has demonstrated that magnesium (Mg) deficiency is associated with a high incidence of Parkinson’s disease (PD). It is known that the systemic administration of MgSO4 is not able to elevate the Mg concentration in cerebrospinal fluid (CSF). This study aims to verify the protective effect of magnesium-L-threonate (MgT) in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model.Methods: C57BL/6J mice were orally administered MgT or MgSO4 for 4 weeks, and received MPTP in the third week. After analysis of open-field and rotarod tests on the last day, tyrosine hydroxylase (TH) immunopositive cells and protein levels were quantified in the substantia nigra pars compacta (SNpc) and striatum. The expression of inducible nitric oxide synthase (iNOS) level was evaluated. Mg concentration in serum and CSF was measured after oral administration of MgSO4 or MgT in normal mice. Mg concentration in the CSF was increased in the mice treated with MgT but not MgSO4.Results: The total distance and mean speed in open-field tests, and the time spent on rotarod in the MgT group were increased, compared with MPTP group. The MgT treatment but not MgSO4 dose-dependently attenuated the loss of TH-positive neurons, and the reduction of the TH expression in the SNpc. The MgT treatment also inhibited the expression of iNOS as measured by immunohistochemistry and Western blots. Double-immunofluorescence staining of TH and iNOS showed iNOS-positive cells were collocalized for TH-positive cells.Conclusion: The treatment with MgT is associated with an increase of Mg in the CSF. MgT, rather than MgSO4, can significantly attenuate MPTP-induced motor deficits and dopamine (DA) neuron loss.Keywords: Parkinson’s disease, magnesium-L-threonate, cerebrospinal fluid, magnesiumShen YDai LTian HXu RLi FLi ZZhou JWang LDong JSun LDove Medical Pressarticleparkinson’s diseasemagnesium-l-threonatecerebrospinal fluidmagnesiumNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 3143-3153 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	parkinson’s disease magnesium-l-threonate cerebrospinal fluid magnesium Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	parkinson’s disease magnesium-l-threonate cerebrospinal fluid magnesium Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Shen Y Dai L Tian H Xu R Li F Li Z Zhou J Wang L Dong J Sun L Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease
description	Yanling Shen,1,2,* Ling Dai,1,* Haibo Tian,1,3 Runnan Xu,1 Fuying Li,4 Zhuohang Li,1 Jeremy Zhou,5 Liping Wang,5 Jianghui Dong,1,5 Liyuan Sun1,4 1Department of Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic of China; 2Department of Pathology, Affiliated Chenggong Hospital, Xiamen University, Xiamen, Fujian 361000, People’s Republic of China; 3Department of Pathology, Fuling Central Hospital of Chongqing City, Chongqing 408099, People’s Republic of China; 4Department of Neurology and Neurological Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan; 5School of Pharmacy and Medical Sciences, and UniSA Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia*These authors contributed equally to this workCorrespondence: Jianghui DongDepartment of Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic of ChinaTel +86-773-3680651Fax +86-773-3680230Email Jianghui.dong@mymail.unisa.edu.auLiyuan SunDepartment of Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic of ChinaTel +86-773-5893516Fax +86-773-5898939Email sunly@glmc.edu.cnPurpose: Epidemiology research has demonstrated that magnesium (Mg) deficiency is associated with a high incidence of Parkinson’s disease (PD). It is known that the systemic administration of MgSO4 is not able to elevate the Mg concentration in cerebrospinal fluid (CSF). This study aims to verify the protective effect of magnesium-L-threonate (MgT) in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model.Methods: C57BL/6J mice were orally administered MgT or MgSO4 for 4 weeks, and received MPTP in the third week. After analysis of open-field and rotarod tests on the last day, tyrosine hydroxylase (TH) immunopositive cells and protein levels were quantified in the substantia nigra pars compacta (SNpc) and striatum. The expression of inducible nitric oxide synthase (iNOS) level was evaluated. Mg concentration in serum and CSF was measured after oral administration of MgSO4 or MgT in normal mice. Mg concentration in the CSF was increased in the mice treated with MgT but not MgSO4.Results: The total distance and mean speed in open-field tests, and the time spent on rotarod in the MgT group were increased, compared with MPTP group. The MgT treatment but not MgSO4 dose-dependently attenuated the loss of TH-positive neurons, and the reduction of the TH expression in the SNpc. The MgT treatment also inhibited the expression of iNOS as measured by immunohistochemistry and Western blots. Double-immunofluorescence staining of TH and iNOS showed iNOS-positive cells were collocalized for TH-positive cells.Conclusion: The treatment with MgT is associated with an increase of Mg in the CSF. MgT, rather than MgSO4, can significantly attenuate MPTP-induced motor deficits and dopamine (DA) neuron loss.Keywords: Parkinson’s disease, magnesium-L-threonate, cerebrospinal fluid, magnesium
format	article
author	Shen Y Dai L Tian H Xu R Li F Li Z Zhou J Wang L Dong J Sun L
author_facet	Shen Y Dai L Tian H Xu R Li F Li Z Zhou J Wang L Dong J Sun L
author_sort	Shen Y
title	Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease
title_short	Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease
title_full	Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease
title_fullStr	Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease
title_full_unstemmed	Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease
title_sort	treatment of magnesium-l-threonate elevates the magnesium level in the cerebrospinal fluid and attenuates motor deficits and dopamine neuron loss in a mouse model of parkinson’s disease
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/e486498656c3424b9adc2150c98bee6b
work_keys_str_mv	AT sheny treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT dail treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT tianh treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT xur treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT lif treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT liz treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT zhouj treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT wangl treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT dongj treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease AT sunl treatmentofmagnesiumlthreonateelevatesthemagnesiumlevelinthecerebrospinalfluidandattenuatesmotordeficitsanddopamineneuronlossinamousemodelofparkinsonsdisease
_version_	1718398036893237248

Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson’s disease

Ejemplares similares